Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ICVB-1042 |
| Synonyms | |
| Therapy Description |
ICVB-1042 is an oncolytic adenovirus that selectively infects tumor cells, which may result in lysis of tumor cells and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 681). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ICVB-1042 | ICVB 1042|ICVB1042 | ICVB-1042 is an oncolytic adenovirus that selectively infects tumor cells, which may result in lysis of tumor cells and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 681). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05904236 | Phase I | ICVB-1042 | Safety and Tolerability of Intravenous Administration of ICVB-1042 | Terminated | USA | 0 |